BCAX shares are trading approximately 11% lower in Monday premarket activity, with shares indicated near ~$20.10, compared to Friday's closing price of $22.58. The primary catalyst is Bicara Therapeutics' Q1 2026 earnings report, released before the market opened on May 11, 2026, which revealed a widening net loss of $56.2 million.

Analysts expect Q4 FY2026 revenue of approximately $830 million and adjusted EPS of $0.90, following strong Q3 results. Nextpower's fiscal year ends March 31; Q4 covers late December 2025 to March 31, 2026.

Ecopetrol's Q1 2026 earnings are scheduled for release on May 12, 2026, after market close, with a conference call on May 13. Company-provided preliminary guidance projects net profit of COP 2.0-3.0 trillion, revenue of COP 27.0-30.0 trillion, and EBITDA of COP 12.0-14.0 trillion.

Analysts expect Q1 2026 EPS of $0.12, down from $0.15 in Q1 2025. Revenue consensus stands at $3.85 billion, reflecting strong growth driven by higher LNG volumes.

Analysts expect Q1 2026 EPS of $2.09, a significant increase from $1.07 in Q1 2025. Consensus revenue estimate stands at approximately $632–$634 million, driven by higher gold prices and steady GEOs (Gold Equivalent Ounces, a measure converting other metals and energy production to gold ounces).

Analysts expect Q1 2026 revenue of approximately $617 million, up 5% from $586 million in Q1 2025. Consensus EPS estimate stands at $0.03, reflecting a sharp decline from $0.20 in the year-ago quarter amid higher costs.

Analysts expect Q1 2026 revenue of approximately $4.1 million, a significant jump from $1.5 million in Q1 2025. Consensus EPS estimate is a loss of $0.04 per share, improving from -$0.08 in the year-ago quarter.

Ovintiv is set to report Q1 2026 earnings after market close on May 11, 2026, with a conference call on May 12. Analysts expect consensus EPS of approximately $1.83-$1.85, up from $1.42 adjusted in Q1 2025.

Analysts expect Q1 2026 revenue of approximately $38 million, a substantial increase from prior quarters driven by gateway sales and government contracts. Consensus EPS estimate stands at -$0.23, reflecting ongoing investments in satellite production and launches.

Analysts expect Q4 fiscal 2026 revenue of approximately $1.60 billion, up about 8% year-over-year. Consensus adjusted EPS estimate stands at $2.89, reflecting 5.5% growth from $2.74 in the prior-year quarter.

Analysts expect Q3 fiscal 2026 EPS of $1.02, down 7.3% year-over-year from $1.10. Consensus revenue forecast stands at $3.79 billion, a 13.2% decline from $4.37 billion last year.

Analysts expect Q1 2026 EPS of $0.17-$0.19, with consensus revenue around $2.91-$2.98 billion USD. Focus on mobile postpaid growth, fixed broadband (FTTH) expansion, and EBITDA margins amid Brazil's competitive telecom market.

Analysts expect Q1 2026 revenue of $717 million, reflecting continued expansion in stablecoin infrastructure. Consensus EPS estimate stands at $0.15-$0.18 per share, down slightly from prior revisions.

Analysts expect Q1 2026 Real Estate FFO (a key metric for REITs, measuring funds from operations excluding certain items) of $2.98 per share, slightly down from $2.95 year-over-year. Consensus revenue forecast stands at $1.57 billion, reflecting 6.4% growth from the prior-year quarter.

Analysts expect Q1 2026 EPS of $0.93, a 50% rise from $0.62 in Q1 2025. Consensus revenue forecast stands at $26.2 billion, up 24.4% year-over-year.

LTH stock rose +14% over the past 30 days, driven primarily by strong Q1 2026 earnings that beat estimates on revenue and EPS, sparking a multi-day rally. Over the past quarter, the stock gained +7%, supported by membership growth, higher dues, and raised full-year guidance amid a focus on premium positioning.

ADI stock surged +19% over the past 30 days, driven by strong sector momentum in analog semiconductors and anticipation ahead of Q2 earnings. Over the past quarter, shares climbed +29%, fueled by robust Q1 fiscal 2026 results with 30% revenue growth and record data center orders.

SIRI stock rose approximately +14% over the past 30 days, driven by strong Q1 2026 earnings that beat estimates on revenue and EPS, alongside improved subscriber retention. Over the past quarter, the stock gained around +27%, fueled by content expansions, advertising growth, and positive analyst revisions.

GSK stock declined approximately -14% over the past 30 days, primarily due to a sharp post-Q1 earnings drop amid investor concerns over one-off boosts and general medicines weakness. Over the past quarter, the stock is down around -8%, reflecting volatility after earlier peaks from Q4 strength, offset by recent sector pressures and valuation reassessments.

MDT stock declined approximately -13% over the past 30 days amid analyst price target reductions and concerns over EPS guidance cuts tied to the MiniMed diabetes unit spin-off. Over the past quarter, the stock fell around -25%, reflecting broader pressures from margin challenges, tariff impacts, and sector sentiment.